Search results
Results From The WOW.Com Content Network
Rituximab, sold under the brand name Rituxan among others, is a monoclonal antibody medication used to treat certain autoimmune diseases and types of cancer. [18] It is used for non-Hodgkin lymphoma, chronic lymphocytic leukemia (in children and adults, but not recommended in elderly patients), rheumatoid arthritis, granulomatosis with polyangiitis, idiopathic thrombocytopenic purpura ...
Pemphigus vulgaris is a rare chronic blistering skin disease and the most common form of pemphigus.Pemphigus was derived from the Greek word pemphix, meaning blister. [1] It is classified as a type II hypersensitivity reaction in which antibodies are formed against desmosomes, components of the skin that function to keep certain layers of skin bound to each other.
Roche (RHHBY) announces positive data on rheumatic diseases drug, Rituxan, for pemphigus vulgaris. Skip to main content. Sign in. Mail. 24/7 Help. For premium support please call: 800-290 ...
Pemphigus foliaceus skin eruption on the abdomen of a dog. Pemphigus foliaceus has been recognized in pet dogs, cats, and horses, and is the most common autoimmune skin disease diagnosed in veterinary medicine. PF in animals produces clusters of small vesicles that quickly evolve into pustules. Pustules may rupture, forming erosions or become ...
List of target antigens in pemphigus; List of immunofluorescence findings for autoimmune bullous conditions; List of cutaneous conditions; List of genes mutated in cutaneous conditions; List of histologic stains that aid in diagnosis of cutaneous conditions
Paraneoplastic pemphigus (PNP) is an autoimmune disorder stemming from an underlying tumor. It is hypothesized that antigens associated with the tumor trigger an immune response resulting in blistering of the skin and mucous membranes .
Because of a high immunogenicity of polyclonal antibodies, almost all patients have an acute reaction to the treatment. It is characterized by fever, rigor episodes, and even anaphylaxis. Later during the treatment, some patients develop serum sickness or immune complex glomerulonephritis. Serum sickness arises seven to fourteen days after the ...
The treatment starts with an infusion of rituximab. This may be followed by an administration of indium-111 labeled ibritumomab tiuxetan ( 111 In replaces the 90 Y component) to allow the distribution of the medication to be imaged on a gamma camera , before the actual therapy is administered.